{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:42:55Z","timestamp":1761871375290,"version":"build-2065373602"},"reference-count":44,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005002","name":"California Department of Public Health","doi-asserted-by":"publisher","award":["103885"],"award-info":[{"award-number":["103885"]}],"id":[{"id":"10.13039\/100005002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006034","name":"University of Southern California","doi-asserted-by":"publisher","award":["HHSN261201000034C"],"award-info":[{"award-number":["HHSN261201000034C"]}],"id":[{"id":"10.13039\/100006034","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U58DP003862-01"],"award-info":[{"award-number":["U58DP003862-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001808","name":"Public Health Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001808","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009109","name":"Pharmaceuticals Bayer","doi-asserted-by":"publisher","award":["201603311353"],"award-info":[{"award-number":["201603311353"]}],"id":[{"id":"10.13039\/501100009109","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.clml.2019.12.008","type":"journal-article","created":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T16:56:22Z","timestamp":1577206582000},"page":"e184-e194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Patient-level Factors Associated With the Initial Management of Older Adults Diagnosed With Follicular Lymphoma: A Surveillance, Epidemiology, and End Results\u2013Medicare Analysis"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5346-6299","authenticated-orcid":false,"given":"Jean","family":"Yared","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3879-1835","authenticated-orcid":false,"given":"Aakash Bipin","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4977-9508","authenticated-orcid":false,"given":"Madhuram","family":"Nagarajan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8870-0842","authenticated-orcid":false,"given":"Husam","family":"Albarmawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Keating","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sreevalsa","family":"Appukkuttan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8547-1810","authenticated-orcid":false,"given":"Eberechukwu","family":"Onukwugha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2019.12.008_bib1","first-page":"443","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2019.12.008_bib2","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3324\/haematol.2012.082412","article-title":"Long-term follow-up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma","volume":"98","author":"Bachy","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2019.12.008_bib3","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study","volume":"25","author":"Herold","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.12.008_bib4","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.12.008_bib5","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1200\/JCO.2008.17.1561","article-title":"Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study","volume":"27","author":"Hochster","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.12.008_bib6","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.12.008_bib7","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2008.18.1495","article-title":"Follicular lymphoma in the United States: first report of the national LymphoCare study","volume":"27","author":"Friedberg","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.12.008_bib8","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/ajh.24401","article-title":"Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States","volume":"91","author":"Nabhan","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2019.12.008_bib9","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus lenalidomide in advanced untreated follicular lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.12.008_bib10","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly\u00d7 4 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.12.008_bib11","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1182\/blood-2006-10-041863","article-title":"How I treat indolent lymphoma","volume":"109","author":"Gribben","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.12.008_bib12","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/bjh.13316","article-title":"A\u00a0population-based study of prognosis in advanced stage follicular lymphoma managed by watch and wait","volume":"169","author":"El-Galaly","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2019.12.008_bib13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1756-8722-6-45","article-title":"Early stage follicular lymphoma: what is the clinical impact of the first-line treatment strategy?","volume":"6","author":"Michallet","year":"2013","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.clml.2019.12.008_bib14","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/bjh.13895","article-title":"Outcomes following watchful waiting for stage II\u2013IV follicular lymphoma patients in the modern era","volume":"172","author":"Nastoupil","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2019.12.008_bib15","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1200\/JCO.2010.33.4474","article-title":"Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database","volume":"30","author":"Solal-C\u00e9ligny","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"year":"2019","series-title":"B-cell Lymphomas. Version 1","author":"National Comprehensive Cancer Network","key":"10.1016\/j.clml.2019.12.008_bib16"},{"issue":"Suppl 3","key":"10.1016\/j.clml.2019.12.008_bib17","doi-asserted-by":"crossref","first-page":"iii76","DOI":"10.1093\/annonc\/mdu200","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Dreyling","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2019.12.008_bib18","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1002\/cncr.25117","article-title":"Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy","volume":"116","author":"Campbell","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2019.12.008_bib19","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1200\/JCO.1996.14.4.1282","article-title":"Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University","volume":"14","author":"Mac Manus","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.12.008_bib20","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1002\/cncr.25149","article-title":"Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation: a Surveillance, Epidemiology, and End Results database analysis","volume":"116","author":"Pugh","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2019.12.008_bib21","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1186\/1471-2407-10-625","article-title":"Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL)","volume":"10","author":"Griffiths","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clml.2019.12.008_bib22","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1634\/theoncologist.2014-0113","article-title":"Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a Surveillance, Epidemiology, and End Results-Medicare analysis","volume":"19","author":"Hamlin","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2019.12.008_bib23","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.12.008_bib24","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/bjh.13399","article-title":"Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States","volume":"170","author":"Nabhan","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2019.12.008_bib25","doi-asserted-by":"crossref","first-page":"4842","DOI":"10.1002\/cncr.27513","article-title":"Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States: report from the National LymphoCare Study","volume":"118","author":"Nabhan","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2019.12.008_bib26","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1002\/cncr.29491","article-title":"What is the optimal management of early-stage low-grade follicular lymphoma in the modern era?","volume":"121","author":"Vargo","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2019.12.008_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10428194.2011.629897","article-title":"Clinical practice guidelines for first-line\/after-relapse treatment of patients with follicular lymphoma","volume":"52","author":"L\u00f3pez-Guillermo","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2019.12.008_bib28","doi-asserted-by":"crossref","first-page":"942","DOI":"10.3109\/10428194.2014.936013","article-title":"Disparate survival outcomes after front-line chemoimmunotherapy in older patients with follicular, nodal marginal zone and small lymphocytic lymphoma","volume":"56","author":"Olszewski","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"8 Suppl","key":"10.1016\/j.clml.2019.12.008_bib29","first-page":"IV3","article-title":"Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population","volume":"40","author":"Warren","year":"2002","journal-title":"Med Care"},{"year":"2019","series-title":"Permission Requests for NCCN content","key":"10.1016\/j.clml.2019.12.008_bib30"},{"key":"10.1016\/j.clml.2019.12.008_bib31","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.clml.2018.08.015","article-title":"The adverse consequences of initial watchful waiting for patients with follicular lymphoma","volume":"18","author":"Davies","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8 Suppl","key":"10.1016\/j.clml.2019.12.008_bib32","first-page":"IV19","article-title":"Patient demographic and socioeconomic characteristics in the SEER-Medicare database: applications and limitations","volume":"40","author":"Bach","year":"2002","journal-title":"Med Care"},{"key":"10.1016\/j.clml.2019.12.008_bib33","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1634\/theoncologist.2015-0199","article-title":"Patterns of biologics use across treatment lines in elderly (age > 65) Medicare patients with metastatic colon cancer","volume":"21","author":"Bikov","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2019.12.008_bib34","first-page":"628","article-title":"Sequential therapies and the cost-effectiveness of treating metastatic colon cancer patients","volume":"22","author":"Woldemichael","year":"2016","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.clml.2019.12.008_bib35","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/cam4.176","article-title":"Does the type of first-line regimens influence the receipt of second-line chemotherapy treatment? An analysis of 3211 metastatic colon cancer patients","volume":"3","author":"Zheng","year":"2014","journal-title":"Cancer Med"},{"key":"10.1016\/j.clml.2019.12.008_bib36","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial","volume":"362","author":"Ardeshna","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2019.12.008_bib37","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.12.008_bib38","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s00277-016-2668-0","article-title":"Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin\u2019s lymphoma: evidence from a multicenter, retrospective study","volume":"95","author":"Mondello","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2019.12.008_bib39","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2019.12.008_bib40","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJM198412063112303","article-title":"The natural history of initially untreated low-grade non-Hodgkin\u2019s lymphomas","volume":"311","author":"Horning","year":"1984","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.12.008_bib41","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1002\/cncr.23914","article-title":"Ethnic variations in diagnosis, treatment, socioeconomic status, and survival in a large population-based cohort of elderly patients with non-Hodgkin lymphoma","volume":"113","author":"Wang","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2019.12.008_bib42","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3390\/ph7050530","article-title":"Barriers to the access and use of rituximab in patients with non-Hodgkin\u2019s lymphoma and chronic lymphocytic leukemia: a physician survey","volume":"7","author":"Baer","year":"2014","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.clml.2019.12.008_bib43","doi-asserted-by":"crossref","first-page":"983","DOI":"10.3109\/10428194.2014.940583","article-title":"Disparities in receipt of radiotherapy and survival by age, sex and ethnicity among patients with stage I diffuse large B-cell lymphoma","volume":"56","author":"Shah","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2019.12.008_bib44","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.amjmed.2014.12.030","article-title":"Who bears the greatest burden of aggressive treatment of indolent prostate cancer?","volume":"128","author":"Mahal","year":"2015","journal-title":"Am J Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226501932230X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226501932230X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:33:31Z","timestamp":1761870811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226501932230X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S215226501932230X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2019.12.008","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-level Factors Associated With the Initial Management of Older Adults Diagnosed With Follicular Lymphoma: A Surveillance, Epidemiology, and End Results\u2013Medicare Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2019.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}